Literature DB >> 32656945

Optic disc dose reduction in ocular brachytherapy using 125 I notched COMS plaques: A simulation study based on current clinical practice.

Yongsook C Lee1, Shih-Chi Lin1, Yongbok Kim1.   

Abstract

PURPOSE: Although notched Collaborative Ocular Melanoma Study (COMS) plaques have been widely used, optic disc dose reduction by notched COMS plaques has not been discussed in the literature. Therefore, this study investigated optic disc dose reduction in ocular brachytherapy using 125 I notched COMS plaques in comparison with optic disc dose for 125 I standard COMS plaques.
METHODS: For this simulation study, an in-house brachytherapy dose calculation program was developed using MATLAB software by incorporating the American Association of Physicists in Medicine Task Group-43 Update (AAPM TG-43U1) dosimetry formalism with a line source approximation in a homogeneous water medium and COMS seed coordinates in the AAPM TG 129. Using this program, optic disc doses for standard COMS plaques (from 12 to 22 mm in diameter in 2 mm increments) and notched COMS plaques with one seed removed (Case #1, from 12 to 22 mm) and with two seeds removed (Case #2, from 14 to 22 mm) were calculated as a function of tumor margin-to-optic disc distance (DT) for various tumor basal dimensions (BDs) for prescription depths from 1 to 10 mm in 1 mm intervals. A dose of 85 Gy for an irradiation time of 168 h was prescribed to each prescription depth. Then absolute and relative optic disc dose reduction by notched COMS plaques (Cases #1 and #2) was calculated for all prescription depths.
RESULTS: Optic disc dose reduction by notched COMS plaques (Cases #1 and #2) had five unique trends related to maximum optic disc dose reduction and corresponding optimal DT for each BD in each plaque. It increased with increasing prescription depth.
CONCLUSIONS: The results presented in this study would enable the clinician to choose an adequate plaque type among standard and notched 125 I COMS plaques and a prescription depth to minimize optic disc dose.
© 2020 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.

Entities:  

Keywords:  125I; Collaborative Ocular Melanoma Study (COMS); notched plaques; ocular brachytherapy; optic disc dose reduction

Mesh:

Year:  2020        PMID: 32656945      PMCID: PMC7497926          DOI: 10.1002/acm2.12966

Source DB:  PubMed          Journal:  J Appl Clin Med Phys        ISSN: 1526-9914            Impact factor:   2.102


  15 in total

1.  Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations.

Authors:  Mark J Rivard; Bert M Coursey; Larry A DeWerd; William F Hanson; M Saiful Huq; Geoffrey S Ibbott; Michael G Mitch; Ravinder Nath; Jeffrey F Williamson
Journal:  Med Phys       Date:  2004-03       Impact factor: 4.071

2.  The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. COMS Report No. 17.

Authors:  M Diener-West; J D Earle; S L Fine; B S Hawkins; C S Moy; S M Reynolds; A P Schachat; B R Straatsma
Journal:  Arch Ophthalmol       Date:  2001-07

3.  Finger's "slotted" eye plaque for radiation therapy: treatment of juxtapapillary and circumpapillary intraocular tumours.

Authors:  Paul T Finger
Journal:  Br J Ophthalmol       Date:  2007-02-27       Impact factor: 4.638

4.  Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients.

Authors:  C L Shields; J A Shields; J Cater; K Gündüz; C Miyamoto; B Micaily; L W Brady
Journal:  Arch Ophthalmol       Date:  2000-09

5.  Prescribing to tumor apex in episcleral plaque iodine-125 brachytherapy for medium-sized choroidal melanoma: A single-institutional retrospective review.

Authors:  David Thomas Vonk; Yongbok Kim; Cameron Javid; John D Gordon; Baldassarre Stea
Journal:  Brachytherapy       Date:  2015-06-06       Impact factor: 2.362

6.  Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.

Authors:  Sou-Tung Chiu-Tsao; Melvin A Astrahan; Paul T Finger; David S Followill; Ali S Meigooni; Christopher S Melhus; Firas Mourtada; Mary E Napolitano; Ravinder Nath; Mark J Rivard; D W O Rogers; Rowan M Thomson
Journal:  Med Phys       Date:  2012-10       Impact factor: 4.071

7.  The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas.

Authors:  Subir Nag; Jeanne M Quivey; John D Earle; David Followill; James Fontanesi; Paul T Finger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-06-01       Impact factor: 7.038

8.  Plaque radiotherapy for juxtapapillary choroidal melanoma: treatment complications and visual outcomes in 650 consecutive cases.

Authors:  Mandeep S Sagoo; Carol L Shields; Jacqueline Emrich; Arman Mashayekhi; Lydia Komarnicky; Jerry A Shields
Journal:  JAMA Ophthalmol       Date:  2014-06       Impact factor: 7.389

9.  Dosimetric and late radiation toxicity comparison between iodine-125 brachytherapy and stereotactic radiation therapy for juxtapapillary choroidal melanoma.

Authors:  Hatem Krema; Mostafa Heydarian; Akbar Beiki-Ardakani; Daniel Weisbrod; Wei Xu; Normand J Laperriere; Arjun Sahgal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-03-16       Impact factor: 7.038

10.  The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma.

Authors: 
Journal:  Brachytherapy       Date:  2013-12-24       Impact factor: 2.362

View more
  1 in total

1.  Optic Disc Dose Comparison Between 125I and 103Pd Collaborative Ocular Melanoma Study (COMS) Plaques Based on Current Clinical Practice.

Authors:  Yongsook C Lee; Shih-Chi Lin; Yongbok Kim
Journal:  Cureus       Date:  2021-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.